Navigation Links
Radius Raises Additional $15 Million, Increasing Second Private Equity Financing Round to $82.5 Million
Date:11/20/2008

CAMBRIDGE, Mass., Nov. 20 /PRNewswire/ -- Radius Health ("Radius") announced today that it has raised an additional $15 million to its second institutional financing round, increasing total Series C investment to $82.5 million and the total amount raised since the company's inception to $106.5 million. All existing institutional investors participated in the financing, led by MPM Bio IV NVS Strategic Fund and including MPM Capital, The Wellcome Trust, HealthCare Ventures, Oxford Bioscience Partners, BB Biotech Ventures, and Scottish Widows Investment Partnership.

Radius will use the additional funding, along with existing cash resources, to support the continued advancement of the company's clinical and preclinical development programs. Radius anticipates results from its Phase II clinical trial of BA058, a bone anabolic therapy for the treatment of osteoporosis, in the first quarter of 2009. Earlier this year, the company initiated a Phase I clinical trial of RAD1901, a novel SERM (selective estrogen receptor modulator) for the treatment of hot flashes, on which Radius expects to commence a Phase IIa study in the first quarter of 2009. In addition, the company recently announced selection of the first preclinical candidate from its SARM (selective androgen receptor modulator) discovery program for treatment of muscle loss, with an investigational new drug (IND) filing expected in the second quarter of 2009.

"We are extremely pleased with the strong continuing confidence of our investors in Radius' progress," said C. Richard Lyttle, PhD, President and CEO of Radius. "We are finishing 2008 in a strong position, with a broad and maturing portfolio of drug candidates for osteoporosis and women's health, an option agreement with a major pharmaceutical company to license BA058 for late-stage development, and significant cash resources at our disposal."

About Radius (www.radiuspharm.com)

Radius is a leading company in the discovery and development of a new generation of drug therapies for osteoporosis and women's health. Radius has raised $106.5 million in private equity financing since its establishment in 2003 and is based in Cambridge, Massachusetts.

    Contact:
    Nick Harvey
    Chief Financial Officer
    1-617-551-4704


'/>"/>
SOURCE Radius Health
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Radius Selects First Preclinical Candidate From SARM Discovery Program for the Treatment of Muscle Loss and Other Musculoskeletal Conditions
2. Radius Completes Enrollment of Phase II Clinical Trial of BA058 for Osteoporosis
3. Ironwood Raises $50 Million to Advance Linaclotide Through Phase 3
4. ESBATech Raises Additional CHF 23M (USD 22M), Extending Series B Venture Financing
5. Celator Pharmaceuticals Raises Series C Financing in Excess of $22.5 Million
6. Light Sciences Oncology Raises $40.1 Million in Series C Financing
7. Romark Laboratories Raises $18 Million in Institutional Financing
8. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
9. EntreMed Raises $20 Million to Support Clinical Development Program
10. Globus Medical Raises $110 Million in Series E Financing Round
11. AMT Intends to Incorporate Additional Data to its Marketing Authorization Dossier for Glybera(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Mass. and SAN CLEMENTE, Calif. , ... California -based mobile pulmonary function testing company, is now able ... PFT devices developed by ndd Medical Technologies , Inc. ... testing done in hospital-based labs.  Thanks to ndd,s EasyOne PRO ® ... , can get any needed testing done in the comfort ...
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ... company developing innovative inhaled drugs, announced today that it ... Russell Investments reconstituted its comprehensive set of U.S. ... "This is an important milestone for Pulmatrix," said ... increase shareholder awareness of our progress in developing drugs ...
(Date:6/23/2016)... -- MedSource announced today that it has selected Datatrial,s ... choice.  This latest decision demonstrates MedSource,s commitment to ... by offering a state-of-the-art electronic data capture (EDC) ... the EDC platform of choice in exchange for ... long been a preferred EDC platform by our ...
Breaking Medicine Technology:
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library ... City Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ... for fumigation is not a common occurrence, but a necessary one in the event that ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, ... at Work award to iHire in recognition of their exemplary accomplishments in worksite health ... annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. ...
(Date:6/24/2016)... ... ... a crisis. Her son James, eight, was out of control. Prone to extreme mood shifts ... upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife ... and say he was going to kill them. If we were driving on the ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and ... that call for a minimum wage raise to $12 an hour by 2020 and then ... will restore the lost value of the minimum wage, assure the wage floor does not ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic ... Frederick area economy by obtaining investment capital for emerging technology companies. SCP ... that have already resulted in more than a million dollars of capital investment ...
Breaking Medicine News(10 mins):